Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-dir

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Monte Rosa Therapeutics (NASDAQ:GLU

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s

Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degr

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported Phase 1 trial results for its inflammatory dise

Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase

Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-m

In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular

In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular

Monte Rosa Therapeutics shares surged 20.03% premarket as investors awaited clinical data from its e

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Monte Rosa Therapeutics

Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corte

Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's afte

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-

Bank of America Corp DE purchased a new position in Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) in

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have been assigned a consen

Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and Cardiff Oncology (NASDAQ: CRDF - Get Fr

Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperfor

Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under

Monte Rosa Therapeutics is rated a risky Buy, with valuation hinging on the clinical success and mil

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-

Bank of America Corp DE lifted its stake in Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) by 73.3% du

Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy an

Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free sur

Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutat

Dimensional Fund Advisors LP boosted its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ

JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight a

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and

Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweig

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Co

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed th

Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascu

Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and

This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a ye

JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight a

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.45) per share which missed th

CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vi

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and

Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweig

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.55) per share which missed th

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with

Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Ove

Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweig

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and